ArticleTargeted oncology2026
HER2-Mutant Non-Small Cell Lung Cancer Podcast: Finding Patients.
Article in Targeted oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Episode 2 in our podcast series focuses on the critical challenge of identifying patients with HER2-mutant non-small cell lung cancer (NSCLC). We discuss why timely and comprehensive testing for HER2 mutations is vital for optimizing patient outcomes and how next-generation sequencing and molecular profiling are integrated into clinical practice. This episode covers the practical aspects and evolving standards of HER2 mutation testing, including the use of tumor and liquid biopsies, and addresses real-world barriers such as cost, access, and awareness. We also explore potential solutions, such as reflex testing and collaboration with molecular pathologists, to overcome current diagnostic challenges. This episode emphasizes the importance of accurate and early molecular diagnosis in ensuring patients receive the most effective, personalized therapies as the treatment landscape for HER2-mutant NSCLC continues to advance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.